Sparton — FY2012 Earnings Presentation
14 slides from Sparton's earnings presentation, Sep 6, 2012
Slide 1: Fiscal 2012 Year-End Financial Results Conference Call
Exhibit 99.2 Fiscal 2012 Year-End Financial Results Conference Call September 6, 2012
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements herein constitute forward-looking statements within the meaning of the Securities Act of 1933, as amended and the Securities Exchange Act of 1934, as amended. When used herein, words such as “believe,” “expect,” “anticipate,” “project,” “plan,” “estimate,” “w
Slide 3: Today's Agenda
Today’s Agenda • 4 th Quarter Highlights • Fiscal 2012 Fourth Quarter Results • Quarterly Adjusted EPS • Fiscal 2012 Year-End Results • Segmented Operating Results • Liquidity & Capital Resources • Growth Investments Summary • Outlook • Q&A 3
Slide 4: 4th Quarter Highlights
th 4 Quarter Highlights • Adjusted net income of $4.0 million, or $0.40 per share, versus adjusted net income of $2.9 million, or $0.28 per share in the prior year quarter • Adjusted operating margin of 9.9% compared to 7.3% last year • Awarded 12 new business programs with 5 new customers • Quarter
Slide 5: Consolidated Financial Results - Fiscal 2012 Fourth Quarter
Consolidated Financial Results Fiscal 2012 Fourth Quarter (Reported) (Adjusted) (Adjusted) Quarter ended June 30, Quarter ended June 30, YoY 2012 2011 2012 2011 Variance Net Sales $ 61,326 $ 60,902 $ 61,326 $ 60,902 $ 424 Gross Profit 12,261 10,393 12,261 10,393 1,868 20.0% 17.1% 20.0% 17.1% Selling
Slide 6: Quarterly Adjusted EPS
Quarterly Adjusted EPS Diluted $1.00 $0.91 $0.90 $0.80 $0.70 $0.64 $0.60 FY11 YTD $0.50 FY12 YTD $0.40 FY11 $0.30 FY12 $0.20 $0.10 $- Q1 Q2 Q3 Q4 YTD 6
Slide 7: Consolidated Financial Results - Fiscal 2012
Consolidated Financial Results Fiscal 2012 (Reported) (Adjusted) (Adjusted) Fiscal Fiscal YoY 2012 2011 2012 2011 Variance Net Sales $ 223,577 $ 203,352 $ 223,577 $ 203,352 $ 20,225 Gross Profit 38,502 33,168 38,396 33,168 5,228 17.2% 16.3% 17.2% 16.3% Selling and Administrative Expense 22,232 20,84
Slide 8: Sales & Gross Margin Results - Medical
Sales & Gross Margin Results Medical SALES 3 Months Ended June 30, Fiscal SEGMENT 2012 % of Total 2011 % Change 2012 % of Total 2011 % Change Medical $ 28,361 46% $ 27,956 1% $ 110,894 50% $ 98,028 13% Complex Systems 15,688 26% 14,704 7% 53,609 24% 49,835 8% DSS 20,976 34% 22,594 -7% 74,102 33% 69,
Slide 9: Sales & Gross Margin Results - Complex Systems
Sales & Gross Margin Results Complex Systems SALES 3 Months Ended June 30, Fiscal SEGMENT 2012 % of Total 2011 % Change 2012 % of Total 2011 % Change Medical $ 28,361 46% $ 27,956 1% $ 110,894 50% $ 98,028 13% Complex Systems 15,688 26% 14,704 7% 53,609 24% 49,835 8% DSS 20,976 34% 22,594 -7% 74,102
Slide 10: Sales & Gross Margin Results - Defense & Security Systems
Sales & Gross Margin Results Defense & Security Systems SALES 3 Months Ended June 30, Fiscal SEGMENT 2012 % of Total 2011 % Change 2012 % of Total 2011 % Change Medical $ 28,361 46% $ 27,956 1% $ 110,894 50% $ 98,028 13% Complex Systems 15,688 26% 14,704 7% 53,609 24% 49,835 8% DSS 20,976 34% 22,594
Slide 11: Liquidity & Capital Resources
Liquidity & Capital Resources 50,000 0.45 Cash Availability 0.42 ($ in '000) Jun-11 Sep-11 Dec-11 Mar-12 Jun-12 0.4 Cash and equivalents 24,550 26,984 30,610 26,682 46,950 0.36 LOC Availability 17,541 17,533 17,290 16,469 16,277 0.35 Total 42,091 44,517 47,900 43,151 63,227 0.3 0.25 25,588 Debt 25,0
Slide 12: Growth Investments - Fiscal 2012 Summary
Growth Investments Fiscal 2012 Summary Focus:Use growth investments to achieve sustainable year-over-year revenue and profit increases and to further place protective barriers around Sparton. Acquisitions Fiscal 2011 Fiscal 2012 Delphi Medical none Byers Peak New Business Awards New Potential Annual
Slide 13: Fiscal 2013 Outlook
Fiscal 2013 Outlook • Implementation of the strategic growth plan – Continue to gain traction on a nationally focused direct selling effort – Further leverage Viet Nam as a low cost country alternative and in-region provider – Maintain our level of investment in internal research & development to co
Slide 14: Q&A
CA) @) Sparton Q&A 14